Overview
Vipharm is a Polish pharmaceutical company that specializes in the research, production, and promotion of generic and oncological drugs. It focuses on medications used in oncology, palliative care, hematology, neurology, psychiatry, and diabetology, addressing various conditions such as cancer, mental health disorders, and neurological diseases. The company aims to ensure the availability of its products and engages in educational activities for healthcare professionals and patients.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2004-02-01. Active
29 1910 1048 2265 0221 7178 0001
89 1240 1082 1111 0010 1805 8142- 29 1240 6074 1207 0010 2220 9343
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 4, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $897,482 | Polski Fundusz Rozwoju S.A. | |
| Nov 21, 2017 | Aid for research and development projects: industrial research | $664,326 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Nov 21, 2017 | Aid for research and development projects: experimental development | $25,768 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2017-10-01 | Opracowanie innowacyjnej technologii wytwarzania produktu leczniczego o działaniu immunomodulującm i neuroprotekcyjnym | $690,094 | Program Operacyjny Inteligentny Rozwój | |
| 2016-08-01 | Opracowanie innowacyjnej technologii wytwarzania przeciwnowotworowego produktu leczniczego inhibitora różnych receptorowych kinaz tyrozynowych. | $534,613 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
A member of the management board or a commercial proxy independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Jan Rafał Szelejewski (51)  | Shareholder of a joint-stock company, 75.39% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| ICN Polfa RzeszówS.A. | $85,044,250.03 | icnpolfa.pl | |
| PolfarmexS.A. | $73,543,379.32 | polfarmex.pl | |
| Wrocławskie Zakłady Zielarskie HerbapolS.A. | $46,537,868.51 | herbapol.pl | |
| Phytopharm KlękaS.A. | $46,154,888.31 | phytopharm.pl | |
| VercoS.A. | $43,577,172.02 | verco.com.pl | |
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | |
| Poznańskie Zakłady Zielarskie HerbapolS.A. | $31,668,225.77 | herbapol.poznan.pl | |
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | |
| Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o. | $21,462,728.43 | farmapol.pl | |
| Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A. | $14,322,437.53 | ewa-sa.pl |
Change history
| Date | Event |
|---|---|
| 2012-03-15 | Address change (A.f.radziwiłłów 9, 05-850, Ożarów Mazowiecki → A. I F. Radziwiłłów 9, 05-850, Ożarów Mazowiecki) |
| 2011-12-06 | Address change (Przewoźników 11, 03-691, Warszawa → A.f.radziwiłłów 9, 05-850, Ożarów Mazowiecki) |
| 2010-09-29 | Share capital change (4,609,800.00 PLN → 4,156,700.00 PLN) |
| 2004-10-13 | Share capital change (1,779,000.00 PLN → 4,609,800.00 PLN) |
| 2004-01-20 | Address change (Rydygiera 8/35, 01-793, Warszawa → Przewoźników 11, 03-691, Warszawa) |
FAQ
Last updated: 2026-07-09